Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Discontinues Involvement In Matuzumab After Phase II Failure

This article was originally published in PharmAsia News

Executive Summary

Takeda will no longer jointly pursue development of cancer monoclonal antibody matuzumab because the epidermal growth factor receptor antagonist failed to meet primary endpoints in a Phase II trial, the Osaka, Japan-based company announced Feb. 18

You may also be interested in...

ImClone/Bristol Aim To Expand Erbitux's Reach To Asia

ImClone and Bristol-Myers Squibb are attempting to make Erbitux (cetuximab) the first EGFR receptor-inhibiting monoclonal antibody to be available in Japan under a co-development and co-commercialization agreement with Merck KGaA announced Oct. 17

Merck Serono/Takeda Matuzumab Development In Question After Phase II Study

Merck Serono is reconsidering development of its monoclonal antibody matuzumab for the treatment of metastatic colorectal cancer after a Phase II study failed to meet its efficacy endpoint, the company announced Aug. 29

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts